Show simple item record

dc.contributor.author Stires H
dc.contributor.author Heckler MM
dc.contributor.author Fu X
dc.contributor.author Li Z
dc.contributor.author Grasso CS
dc.contributor.author Quist MJ
dc.contributor.author Lewis JA
dc.contributor.author Klimach U
dc.contributor.author Zwart A
dc.contributor.author Mahajan A
dc.contributor.author Győrffy, Balázs
dc.contributor.author Cavalli LR
dc.contributor.author Riggins RB
dc.date.accessioned 2019-03-20T13:03:09Z
dc.date.available 2019-03-20T13:03:09Z
dc.date.issued 2018
dc.identifier 85030330612
dc.identifier.citation journalVolume=471;journalTitle=MOLECULAR AND CELLULAR ENDOCRINOLOGY;pagerange=105-117;journalAbbreviatedTitle=MOL CELL ENDOCRINOL;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/6826
dc.identifier.uri doi:10.1016/j.mce.2017.09.024
dc.description.abstract Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological, and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC). Mounting evidence suggests that estrogen receptor-alpha positive (ER+) ILC has a poor response to Tamoxifen (TAM), but the mechanistic drivers of this are undefined. In the current work, we comprehensively characterize the SUM44/LCCTam ILC cell model system through integrated analysis of gene expression, copy number, and mutation, with the goal of identifying actionable alterations relevant to clinical ILC that can be co-targeted along with ER to improve treatment outcomes. We show that TAM has several distinct effects on the transcriptome of LCCTam cells, that this resistant cell model has acquired copy number alterations and mutations that impinge on MAPK and metabotropic glutamate receptor (GRM/mGluR) signaling networks, and that pharmacological inhibition of either improves or restores the growth-inhibitory actions of endocrine therapy.
dc.format.extent 105-117
dc.relation.ispartof urn:issn:0303-7207
dc.title Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities
dc.type Journal Article
dc.date.updated 2019-03-05T10:52:20Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 3270768
dc.identifier.wos 000447980000011
dc.identifier.pubmed 28935545
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.department MTA TTK/EI/Onkológiai Biomarker Kutatócsoport (Lendület)
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account